Dr. Clay Siegall is co-founder, president and CEO of the Bothell, Washington based biotech company Seattle Genetics. A scientist by training, his focus has long been targeted cancer therapies. Dr. Siegall graduated from the University of Maryland with an undergraduate degree in zoology. He also has a Ph.D. in genetics from George Washington University. Before co-founding Seattle Genetics in 1998, Dr. Siegall worked at a number of very influential organizations involved in cancer research. In addition to his work at Seattle Genetics, he’s also on the board of Ultragenyx Pharmaceutical, Mirna Therapeutics, Inc. and Alder Biopharmaceuticals Inc.
Seattle Genetics is internationally known for its rigorous research, scientific innovation and groundbreaking drug development practices. Dr. Siegall and his staff are driven by their passion to improve treatment outcomes for cancer patients. One of Seattle Genetics most valuable contributions to the field of cancer research is their development of ADCETRIS, an antibody drug conjugate that has been very effective in treating cancer. The company also has almost two dozen other ADCs that are currently in clinical development through their internal and collaborator programs.
A major role Dr. Clay Siegall plays at Seattle Genetics is fundraising. Through licensing agreements with AbbVie, Pfizer, GlaxoSmithKline, Genentech and other companies, he has been able to raise in excess of $300 million. Using public and private financing he has been able to get the company an additional $675 million. These funds have helped the company to do the cutting-edge research for which they are lauded. Under the leadership of Dr. Clay Siegall, Seattle Genetics has emerged as a leader in the development of ADCs and other very effective targeted cancer therapies.
Dr. Siegall’s vision, hard work, effectiveness and business acumen led Ernst & Young to vote him 2012 ‘Entrepreneur of the Year’. Clay Siegall, Ph.D. has also published numerous valuable papers on cancer research and made many other important contributions to the field. Under his direction and guidance Seattle Genetics has emerged has a company that is responsible for providing cancer patients with some of the best targeted cancer treatment outcomes the industry has seen in many years.